Exploring animal models for osteoarthritis drug development

Different animal models offer unique advantages for specific drug development applications. 

Scientists use animal models to study a wide range of diseases, but no single animal model encompasses all sequelae of a particular disease. Preclinical research on osteoarthritis remains challenging because its onset is influenced by different mechanisms, resulting in various symptoms such as joint pain, inflammatory flares, and cartilage lesions. In this webinar brought to you by Inotiv, Jed Pheneger and Alison Bendele will discuss various animal models for osteoarthritis drug development and compare lesion morphologies and pathological mediators of osteoarthritis in these models. 

Topics to be covered

  • Advantages and limitations of current preclinical osteoarthritis models
  • Key morphologic and pathogenic features of various osteoarthritis models
  • Selecting the most applicable animal model for osteoarthritis drug development

Wednesday, August 2nd, 2023 | 2:30 PM - 4:00 PM Eastern Time
This webinar will be available to view live and on demand.


Jed Pheneger

Jed Pheneger

Senior Director of Pharmacology – Inflammation 

Alison M. Bendele, DVM, PhD, DACVP

Alison Bendele, DVM, PhD, DACVP


Sponsored by